Unique ID issued by UMIN | UMIN000041973 |
---|---|
Receipt number | R000047910 |
Scientific Title | Anticoagulant effects of Edoxiaban and those inhibitors in cancer and non-cancer patients with venous thromboembolism. |
Date of disclosure of the study information | 2020/10/05 |
Last modified on | 2024/10/10 18:11:42 |
Anticoagulant effects of Edoxiaban and those inhibitors in patients with venous thromboembolism.
EVE study
Anticoagulant effects of Edoxiaban and those inhibitors in cancer and non-cancer patients with venous thromboembolism.
EVE study
Japan |
Venous thromboembolism (VTE)
Medicine in general | Cardiology | Hematology and clinical oncology |
Surgery in general | Obstetrics and Gynecology | Oto-rhino-laryngology |
Orthopedics | Urology |
Others
NO
Compare the anticoagulant effects of Edoxaban in cancer and non-cancer patients by measuring the PT, APTT and D-dimer value after Edoxaban administration.
Others
Observational study
Exploratory
Others
Not applicable
PT, APTT and D-dimer value after Edoxaban administration.
Compare delta PT and delta APTT (difference in PT or APTT value before and 5 hours after Edoxaban administration) in cancer and non-cancer patients.
Identify the time when D-dimer decrease below 50% of baseline value.
Compare changes of D-dimer value after Edoxaban administration in cancer and non-cancer patients.
Identify factors those inhibit PT and APTT prolongation by Edoxaban administration.
Identify factors those inhibit D-dimer decrease by Edoxaban administration.
Assess recurrent VTE, interruption of Edoxaban administration, major bleeding events, clinically relevant non-major bleeding events and death.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
Patients taking Edoxaban after VTE diagnosis.
Patients under 20 years-old.
Patients with hemodynamically insufficiency.
Patients who need thrombolytic therapy or emergent thrombectomy.
Terminal cancer patients those life prognosis are less than 3 months.
Patients taking Edoxaban, unfractionated heparin or fondaparinux before VTE diagnosis.
800
1st name | Masashi |
Middle name | |
Last name | Yoshida |
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Department of CKD and CVD
700-8558
2-5-1, Shikata-cho, Kitaku, Okayama city, Okayama, Japan
0862357351
yoshid-m@cc.okayama-u.ac.jp
1st name | Masashi |
Middle name | |
Last name | Yoshida |
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Department of CKD and CVD
700-8558
2-5-1, Shikata-cho, Kitaku, Okayama city, Okayama, Japan
0862357351
yoshid-m@cc.okayama-u.ac.jp
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Daiichi Sankyo Co., Ltd.
Profit organization
Japan
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital, Ethics Committee
2-5-1, Shikata-cho, Kitaku, Okayama city, Okayama, Japan
0862356938
Mae6605@adm.okayama-u.ac.jp
NO
2020 | Year | 10 | Month | 05 | Day |
Unpublished
243
Delay expected |
Preparing URLs for releasing protocol and related to results and publications.
No longer recruiting
2019 | Year | 12 | Month | 13 | Day |
2019 | Year | 11 | Month | 08 | Day |
2020 | Year | 10 | Month | 05 | Day |
2023 | Year | 01 | Month | 31 | Day |
2024 | Year | 03 | Month | 31 | Day |
Multicenter cohort study
2020 | Year | 10 | Month | 01 | Day |
2024 | Year | 10 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047910